/

PLX

Protalix BioTherapeutics, Inc. Closed

2.75−0.03 −1.08%USD

NYSE American · as of Oct 13, 16:00 ETAfter hours 2.80 +1.82%

Open

2.80

Prev close

2.78

Day range

2.742.79

52-week range

1.603.19

Volume

966.79K1.29×

Mkt cap

221.57M

P/E ttm

11.96

Fwd P/E

4.44

EPS ttm

0.2300

Div yield

0.00%

Earnings

Aug 12, 2026

From 52w high

−13.79%

Price Chart

Yahoo Finance · delayed

PLXOct 13, 2026O 2.80H 2.80L 2.74C 2.75−0.03 (−1.08%)Vol 966.80K

SMA 502.60
SMA 2002.37

1Y change +12.24% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PLX Protalix BioTherapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +0.73%
1 month: +4.17%
3 months: +19.05%
6 months: +16.53%
Year to date: +52.78%
1 year: +12.24%

Valuation & ownership

Market cap: 221.57M
Enterprise value: 190.12M
P/E (ttm): 11.96
Forward P/E: 4.44
PEG ratio: —
Price / book: 3.10
Price / sales (ttm): 2.75
EV / EBITDA: 7.65
EPS (ttm): 0.2300
EPS (forward): 0.6200
Beta (5y monthly): -0.09
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 80.57M
Float: 77.45M
Short % of float: 3.93%
Short ratio (days): 4.16
Held by insiders: 3.88%
Held by institutions: 18.42%
Avg volume (3m): 749.96K
50-day average: 2.59
200-day average: 2.36
52-week change: +12.24%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 55.9
vs 50-day SMA: +5.95%
vs 200-day SMA: +16.13%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 3.50%
Realised vol (20d, ann.): 26.0%
From 52-week high: −13.79%
From 52-week low: +71.87%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

11.00

+300.00% implied

Low 10.00Median 11.00High 12.00

Recommendation trend

Now1 / 0 / 0
1m ago1 / 0 / 0

Buy / hold / sell counts

Recent actionsAll (UPDN) →

DES

About Protalix BioTherapeutics, Inc.

Yahoo Finance profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.

Sector: Healthcare
Industry: Biotechnology
Employees: 226
Headquarters: Hackensack, NJ, United States
Website: protalix.com
Officers: Mr. Dror Bashan President, CEO & Director
Mr. Gilad Mamlok Senior VP, CFO Treasurer & Secretary
Mr. Yaron Naos B.Sc., MBA SVP & COO
Ms. Yael Fellous

SEAS

Seasonality · PLX

2007–2026 · monthly returns

Strongest month Jan +12.63%Weakest month Oct −5.35%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	30.0	23.1	-24.7	-0.9	-1.9	10.4	1.7	8.4	7.4	-0.4			+52.8%
2025	29.3	-4.1	9.9	19.9	-49.5	-4.5	-1.4	6.2	43.2	6.8	-24.9	1.1	−4.3%
2024	-18.5	12.4	-22.7	-9.5	-0.9	3.5	-7.7	-13.0	8.5	14.7	47.0	9.3	+5.6%
2023	13.9	24.4	8.2	32.4	-24.8	-4.3	-20.0	18.1	-12.2	0.6	-9.6	17.9	+29.9%
2022	1.2	0.0	26.2	9.4	1.7	-7.6	-2.8	4.7	-6.3	-1.0	6.8	24.5	+65.1%
2021	20.7	11.9	-9.0	-24.9	-9.3	-37.2	-20.9	8.6	-18.9	-15.0	-17.7	-10.8	−77.1%
2020	12.8	-10.8	-28.8	59.6	-10.9	13.5	-5.5	2.8	5.2	-15.5	9.8	1.1	+10.7%
2019	58.1	-4.1	-6.4	0.0	-15.9	27.0	-21.3	-43.2	0.0	4.8	40.9	5.8	+5.8%
2018	4.5	-2.9	-19.4	-24.1	19.5	-12.2	14.0	-2.0	52.1	-32.9	-12.2	-27.9	−53.0%
2017	40.0	66.7	29.5	-31.6	-3.2	-6.7	-19.0	-22.1	9.4	34.5	-11.5	-4.3	+46.7%
2016	-16.7	-2.4	1.2	-1.2	-3.6	-20.0	1.6	-7.7	-5.0	-17.5	19.1	-19.6	−55.9%
2015	8.7	-4.0	-7.3	23.6	-11.8	0.5	-15.9	-10.4	-19.7	-11.9	0.0	-1.9	−44.6%
2014	9.3	13.6	-5.2	-11.6	-1.2	-8.8	-9.9	-21.0	-6.9	-9.1	-4.5	-12.4	−52.7%
2013	-1.5	11.9	-4.0	3.3	-10.2	-3.5	9.0	-2.8	-12.9	-3.1	-10.5	-1.0	−25.0%
2012	15.2	-6.0	19.3	9.1	-7.1	-11.3	1.6	-6.7	-4.6	-6.8	14.9	-6.5	+5.3%
2011	-2.5	-27.5	-13.8	14.6	-11.0	1.0	2.9	-26.2	-3.2	32.8	-0.7	-18.8	−50.6%
2010	3.5	-1.3	-3.0	3.2	-10.3	0.7	6.9	18.1	12.7	11.2	-9.5	14.2	+50.8%
2009	27.7	-2.1	-13.0	46.0	30.1	18.9	53.8	-7.9	29.1	14.8	4.0	-32.9	+259.8%
2008	-3.2	1.8	-21.5	4.2	27.7	-22.6	-3.0	-10.6	-5.1	-23.8	-29.4	53.3	−45.9%
2007	37.7	-26.1	84.2	-13.9	-6.8	7.4	-50.1	93.2	32.9	-85.2	-28.4	-6.8	−79.6%

INSD

Insider Activity · PLX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Dec 18, 2025	Bashan DrorChief Executive Officer	Purchase at price 1.81 per share.	56K	$101.36K
Nov 17, 2025	Bar Shalev AmosDirector	Sale at price 1.87 per share.	168	$314
Sep 2, 2025	Melincoff Gwen ADirector	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Sep 2, 2025	Bar Shalev AmosDirector	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Sep 2, 2025	Boudes Pol FDirector	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Sep 2, 2025	Schwartz AharonDirector	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Sep 2, 2025	Naos YaronOfficer	Stock Award(Grant) at price 0.00 per share.	25K	—
Sep 2, 2025	Bashan DrorChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	195K	—
Sep 2, 2025	Forster EliotDirector	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Sep 2, 2025	Ben Zvi ShmuelDirector	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Sep 2, 2025	Elze ChristianDirector	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Jun 9, 2025	Schwartz AharonDirector	Purchase at price 1.60 per share.	129K	$205.88K

13F

Investors Holding PLX

latest 13F filings of 29 followed managers

Investors holding PLX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$2.6M	0.00%	1.10M	−11%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

PLX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PLX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Protalix BioTherapeutics, Inc.

Seasonality · PLX

Insider Activity · PLX

Congress Trades · PLX

Investors Holding PLX

Investors Holding PLX

Seasonality · PLX

Insider Activity · PLX

Congress Trades · PLX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Protalix BioTherapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News